• Home
• Board Member Login
• Advertising
• Useful Links
• Contact Us
• Search
  • SEARCH AATOD

Policies

• Policy Statements
  • AATOD Guidelines for Guest Medication
  • AATOD Guidelines for Using Naltrexone (Vivitrol) in OTPs
  • AATOD’s Five-Year Plan
  • AATOD’s Response to SAMHSA’s Federal Register Notice of May 16, 2013 in Updating the Accreditation Guidelines for OTPs
  • Challenges and Opportunities (July 2012)
  • Guidance to OTPs Concerning the Use of Prescription Monitoring Program (PMP) Databases
  • Increasing Access to Medication to Treat Opioid Addiction – Increasing Access for the Treatment of Opioid Addiction with Medications
  • Medication-Assisted Treatment for Opioid Addiction: Challenges and Solutions – June 2011
  • Overdose Prevention
  • Proposal to Increase Medicaid Utilization for OTPs
  • Recommendations in Siting New OTPs in the United States
  • Washington State Prescription Monitoring Program – Notice to Patient of Evergreen Treatment Services
  • MAT for Opioid Addiction in the Criminal Justice System
• Whitepapers
  • Whitepaper # 3
    • Improving Access to Pharmacotherapy for Opioid Use Disorder within the Criminal Justice System
    • Increasing Access to Medication Assisted Treatment in Drug Courts
    • Methods of Engaging Family Courts and Child Protective Services Through Opioid Treatment Programs and DATA 2000 Practices
• End of Year Reports
• AATOD Fact Sheets
  • Medication-Assisted Treatment for Opioid Use Disorder in the Criminal Justice System
    • Introduction
    • Evidence-Based Arguments in Support of MAT for Opioid Use Disorders
    • The Medications and Their Effectiveness
    • Myths About Medication
    • Policy and Legal Considerations Related to use of MAT for Opioid Use Disorder
    • Conclusions
    • References
  • Medication-Assisted Treatment for Opioid Use Disorders
• Legislation